PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases
- PMID: 22143250
- DOI: 10.1097/MNH.0b013e32834de526
PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases
Abstract
Purpose of review: Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated nuclear transcription factor that regulates many important physiological processes including glucose and lipid metabolism, energy homeostasis, cell proliferation, inflammation, immunity and reproduction. The current review aims to summarize and discuss recent findings evaluating the protective effects of PPARγ against kidney diseases with a focus on diabetic nephropathy. We will also delineate the potential underlying mechanisms.
Recent findings: PPARγ plays important roles in renal physiology and pathophysiology. Agonists of PPARγ exert protective effects against various kidney diseases including diabetic nephropathy, ischemic renal injury, IgA nephropathy, chemotherapy-associated kidney damage, polycystic kidney diseases and age-related kidney diseases via both systemic and renal actions.
Summary: PPARγ agonists are effective in delaying and even preventing the progression of many renal diseases, especially diabetic nephropathy. PPARγ may represent a promising target for the treatment of renal diseases.
Similar articles
-
PPARγ and chronic kidney disease.Pediatr Nephrol. 2011 Mar;26(3):347-51. doi: 10.1007/s00467-010-1602-2. Epub 2010 Jul 30. Pediatr Nephrol. 2011. PMID: 20676693 Review.
-
[The role of PPARgamma agonists in kidney diseases].Nihon Rinsho. 2010 Feb;68(2):317-22. Nihon Rinsho. 2010. PMID: 20158103 Review. Japanese.
-
Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.J Ethnopharmacol. 2016 Aug 2;189:238-49. doi: 10.1016/j.jep.2016.05.033. Epub 2016 May 17. J Ethnopharmacol. 2016. PMID: 27224243
-
Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.Curr Opin Nephrol Hypertens. 2008 May;17(3):282-5. doi: 10.1097/MNH.0b013e3282f9b1c0. Curr Opin Nephrol Hypertens. 2008. PMID: 18408479 Review.
-
Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.Clin Sci (Lond). 2009 Jan;116(1):17-26. doi: 10.1042/CS20070462. Clin Sci (Lond). 2009. PMID: 19037881 Review.
Cited by
-
Pioglitazone Modulates the Vascular Contractility in Hypertension by Interference with ET-1 Pathway.Sci Rep. 2019 Nov 11;9(1):16461. doi: 10.1038/s41598-019-52839-6. Sci Rep. 2019. PMID: 31712626 Free PMC article.
-
Mechanism of Cornus Officinalis in Treating Diabetic Kidney Disease Based on Network Pharmacology.Evid Based Complement Alternat Med. 2022 Jul 9;2022:1799106. doi: 10.1155/2022/1799106. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35855831 Free PMC article.
-
Toll-like Receptor 4 Signaling Pathway in the Protective Effect of Pioglitazone on Experimental Immunoglobulin A Nephropathy.Chin Med J (Engl). 2017 Apr 20;130(8):906-913. doi: 10.4103/0366-6999.204101. Chin Med J (Engl). 2017. PMID: 28397719 Free PMC article.
-
Saroglitazar Ameliorates Pulmonary Fibrosis Progression in Mice by Suppressing NF-κB Activation and Attenuating Macrophage M1 Polarization.Medicina (Kaunas). 2025 Jun 26;61(7):1157. doi: 10.3390/medicina61071157. Medicina (Kaunas). 2025. PMID: 40731787 Free PMC article.
-
An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy.Front Endocrinol (Lausanne). 2022 Sep 21;13:967822. doi: 10.3389/fendo.2022.967822. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36213291 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous